Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

False positives in screening tests

In many jurisdictions, tests for human immunodeficiency virus (HIV) are required screening for pregnant women. Some even suggest screening the entire population for HIV. The rationale is to administer powerful antiretroviral drugs to healthy individuals to "prevent transmission."

10 Mar 2010

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

University of Michigan Health System evaluates factors that can reduce hospital deaths

Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.

9 Mar 2010

Cantel Medical's fiscal 2010 second-quarter net income up 29%

CANTEL MEDICAL CORP. reported a 29% increase in net income to $4,876,000, or $0.29 per diluted share, on a 6.7% increase in sales to $66,587,000 for the second quarter ended January 31, 2010. This compares with net income of $3,774,000, or $0.23 per diluted share, on sales of $62,420,000 for the second quarter ended January 31, 2009.

9 Mar 2010

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration meets today to review and discuss the company's New Drug Application for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis.

9 Mar 2010

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida, has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its DNA into human chromosomes.

9 Mar 2010

Saddle Up Safely campaign: Understanding how diseases of horse can affect humans

Although it is rare for humans to pick up a disease from a horse, education on the subject is the best source of prevention, and the Saddle Up Safely campaign addresses diseases, clinical signs and professional advice in a new booklet on this topic.

9 Mar 2010

Tetanus, hepatitis vaccination campaign launched in Chile amid fears of disease outbreaks

"Chile launched a hepatitis and tetanus vaccination campaign Friday and doctors warned of outbreaks of diarrhea and infection among thousands of people displaced by the earthquake and the tsunami that heavily damaged or destroyed 36 hospitals and made garbage dumps of coastal towns and cities," the Associated Press reports. So far, no dysentery outbreaks or other communicable diseases had been reported, Chile's health ministry said, adding that it believed it had adequate amounts of tetanus and hepatitis vaccinations.

9 Mar 2010

PDVI launches new web site for tracking dengue fever epidemics

PDVI, a program of the International Vaccine Institute funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide.

9 Mar 2010

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.

8 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Abt Associates receives two new contracts to evaluate effectiveness of H1N1 vaccine

The Centers for Disease Control and Prevention has awarded Abt Associates two new contracts to evaluate the effectiveness of the H1N1 vaccine among health care workers and children under the age of 18.

6 Mar 2010

Study shows clear link between Vitamin D levels and accumulation of fat in muscle tissue

There's an epidemic in progress, and it has nothing to do with the flu. A ground-breaking study published in the March 2010 Journal of Clinical Endocrinology and Metabolism found an astonishing 59 per cent of study subjects had too little Vitamin D in their blood. Nearly a quarter of the group had serious deficiencies (less than 20 ng/ml) of this important vitamin.

6 Mar 2010

Lancet World Report examines GAVI's funding gap

Lancet World Report examines the challenges ahead for the GAVI Alliance, which after a decade of "steadily increasing financing" is now "facing a funding shortfall for the next decade that could hamper the roll-out of new vaccines." GAVI leaders attribute the funding challenges to the global economic crisis, which has kept government aid budgets from increasing, according to the Lancet.

6 Mar 2010

New anti-tumour vaccine for mesothelioma shows promising results

A vaccine against mesothelioma, a cancer associated with exposure to asbestos, has shown early promise in its first clinical trial.

5 Mar 2010

Investigators disprove reports that well-fed children are more vulnerable to dengue virus

A new study led by St. Jude Children's Research Hospital investigators disproves reports that well-fed children are more vulnerable to the dengue virus. Mosquitoes spread the virus, which can cause severe flu-like symptoms and sometimes lethal complications.

5 Mar 2010

NanoViricides files Universal Form S-3 Shelf Registration with SEC

NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities.

5 Mar 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Celltrion develops novel human monoclonal antibodies against influenza virus infection

False positives in screening tests

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

University of Michigan Health System evaluates factors that can reduce hospital deaths

Cantel Medical's fiscal 2010 second-quarter net income up 29%

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Saddle Up Safely campaign: Understanding how diseases of horse can affect humans

Tetanus, hepatitis vaccination campaign launched in Chile amid fears of disease outbreaks

PDVI launches new web site for tracking dengue fever epidemics

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Presentation of results from open-label extension study of Xenazine

Abt Associates receives two new contracts to evaluate effectiveness of H1N1 vaccine

Study shows clear link between Vitamin D levels and accumulation of fat in muscle tissue

Lancet World Report examines GAVI's funding gap

New anti-tumour vaccine for mesothelioma shows promising results

Investigators disprove reports that well-fed children are more vulnerable to dengue virus

NanoViricides files Universal Form S-3 Shelf Registration with SEC

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in